Interleukin-2 (r-IL-2)-induced lymphokine-activated killer (LAK) cells and their precursors express the VGO1 antigen

Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: The Lymphokine-activated killer cell phenomenon: Lysis of fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 15:823–830, 1982 Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachmann LB, Wilson DJ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into LAK cells. J Exp Med 158:1356–1362, 1983 Henney CS, Kuribayashi K, Kern DE, Gillis S: Interleukin-2 augments natural killer cell activity. Nature 291:335, 1981 Ortaldo John R, Mason AT, Gerard JP, Henderson LE, Farrar W, Hopkins RF III, Herberman RB, Rabin H: Effects of natural and recombinant IL-2 on regulation of IFN production and natural killer activity: Lack of involvement of the TAC antigen for these immunoregulatory effects. J Immunol 133:779–783, 1984 Itoh K, Shiba K, Shimizu Y, Suzuki R, Kumagai K: Generation of activated killer (AK) cells by recombinant interleukin-2 (rIL-2) in collaboration with interferon (IFN). J Immunol 134:3124–3129, 1985 Trinchieri GM, Matsumoto-Kobayaski, Clark SC, Seehra J, London L, Perussia B: Response of resting human peripheral blood natural killer cells to interleukin-2. J Exp Med 160:1147–1169, 1984 Van de Griend RJ, Cees, Ronteltap PM, Gravekamp C, Monnikendam D, Bolhus RLH: Interferon-B and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3− natural killer cell-derived clones rather than that of the T3+ clones. J Immunol 136:1700–1706, 1986 Lotzova E, Savary CA, Herberman RB: Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 138:2718–2727, 1987 Adler A, Chervenick P, Whiteside T, Lotzova E, Herberman R: Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. 1. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:709–716, 1988 Itoh K, Tilden A, Balch C: Role of interleukin 2 and a serum factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells. Cancer Res 45:3173–3178, 1985 Barlozzari T, Leonhardt J: J Immunol 134:2783–2789, 1985 Heberman RB, Ortaldo JR: Natural killer cells: Their role in defense against disease. Science 214:24–30, 1981 Oldham RK: Natural killer cells: History and significance. J Biol Response Mod 1:217–223, 1984 Rosemberg S: Lymphokine activated killer cells: A new approach to immunotherapy of cancer. J Natl Cancer Inst 75:595, 1985 Herberman R: Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleen. Immunol Today 8:178–181, 1987 Itoh K, Tilden A, Kumagai K, Balch CM: Leu11+ lymphocytes with NK activity are precursors of recombinant inter-leukin-2 induced activated killer cells. J Immunol 134:802–806, 1985 Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G: Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol 135:2133, 1983 Lanier LL, Benike CJ, Phillips JH, Engleman EG: Recombinant interleukin-2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol 134:794–801, 1985 Ferrini S, Miescher S, Zocchi M, Von Fliedner V, Moretta A: Phenotypic and functional characterization of recombinant interleukin 2 (rIL-2)-induced activated killer cells: Analysis at the population and clonal levels. J Immunol 138:1297–1302, 1987 Hercend T, Griffin JD, Bensussan A, Schmidt RE, Edson MA, Breunan A, Murray C, Daley JF, Schlossman SF, Ritz J: Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKHIA, and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest 75:932, 1985 Shau H, Golub SH: Signals for activation of natural killer and natural killer-like activity. Nat Immun Cell Growth Regul 4:113–119, 1985 Zocchi MR, Bottino C, Ferrini S, Moretta L, Moretta A: A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function. J Exp Med 166:319–326, 1987 Borst J, van de Griend R, van Oostveen J, Ang S, Melief C, Seidman J, Bolhuis R: A T-cell receptor/CD3 complex found on cloned functional lymphocytes. Nature 325:683–688, 1987 Denegri JF, Gilks CB, Altin M, Peterson J, Lafleur L: A novel lymphocyte activation antigen present on allospecific primed lymphocytes and defined by the monoclonal antibody VGO1I. Transplantation 45:978–984, 1988 Denegri JF: Characterization of peripheral blood monoclonal cells expressing the VGO1 antigen: Their NK and memory function. Hum Immunol 22:39–50, 1988 Gillis SO, Ferm WO, Smith K: T cell growth factor: Parameters of production and a quantitative microassay for activity. J Immunol 120:2027, 1978 Phillips J, Lanier L: Dissection of the lymphokine-activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814–825, 1986 Damle N, Doyle L, Bradley E: Interleukin-2 activated human killer cells are derived from phenotypically heterogenous precursors. J Immunol 137:2814–2822, 1986